MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

January 23, 2024

https://www.globenewswire.com/news-release/2024/01/23/2814060/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Imugene-to-Advance-their-Cancer-Immunotherapy-Programs.html

ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq:MXCT; LSE:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Imugene, (ASX:IMU), a clinical-stage immuno-oncology and cell therapy company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors, today announced the signing of a strategic platform license (SPL).

Read more at globenewswire.com

Related news for (MXCT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.